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MaBACKGROUND Anticoagulation for mechanical heart valves during pregnancy is essential to prevent thromboembolic
events. Each regimen has drawbacks with regard to maternal or fetal risk.
OBJECTIVES This meta-analysis sought to estimate and compare the risk of adverse maternal and fetal outcomes in
pregnant women with mechanical heart valves who received different methods of anticoagulation.
METHODS Studies were identiﬁed using a Medline search including all publications up to June 5, 2016. Study inclusion
required reporting of maternal death, thromboembolism, and valve failure, and/or fetal spontaneous abortion, death, and
congenital defects in pregnant women treated with any of the following: 1) a vitamin K antagonist (VKA) throughout
pregnancy; 2) low-molecular-weight heparin (LMWH) throughout pregnancy; 3) LMWH for the ﬁrst trimester, followed
by a VKA (LMWH and VKA); or 4) unfractionated heparin for the ﬁrst trimester, followed by a VKA (UFH and VKA).
RESULTS A total of 800 pregnancies from 18 publications were included. Composite maternal risk was lowest with VKA
(5%), compared with LMWH (16%; ratio of averaged risk [RAR]: 3.2; 95% conﬁdence interval [CI]: 1.5 to 7.5), LMWH and
VKA (16%; RAR: 3.1; 95% CI: 1.2 to 7.5), or UFH and VKA (16%; RAR: 3.1; 95% CI: 1.5 to 7.1). Composite fetal risk was
lowest with LMWH (13%; RAR: 0.3; 95% CI: 0.1 to 0.8), compared with VKA (39%), LMWH and VKA (23%), or UFH and
VKA (34%). No signiﬁcant difference in fetal risk was observed between women taking #5 mg daily warfarin and those
with an LMWH regimen (RAR: 0.9; 95% CI: 0.3 to 2.4).
CONCLUSIONS VKA treatment was associated with the lowest risk of adverse maternal outcomes, whereas the use of
LMWH throughout pregnancy was associated with the lowest risk of adverse fetal outcomes. Fetal risk was similar
between women taking #5 mg warfarin daily and women treated with LMWH. (J Am Coll Cardiol 2017;69:2681–91)
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CI = conﬁdence interval
LMWH = low-molecular-
weight heparin
MHV = mechanical heart valve
RAR = ratio of averaged risk
UFH = unfractionated heparin
VKA = vitamin K antagonist
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warfarin, are effective at reducing thrombo-
embolic events and are standard therapy for
anticoagulation in the absence of contraindi-
cations (2). However, several studies have
demonstrated teratogenicity of warfarin dur-
ing the sixth to ninth weeks of pregnancy
(3–5), and some studies have found a high
rate of fetal loss in pregnant women taking
warfarin (6). Therefore, many patients andphysicians have been reluctant to use a VKA during
pregnancy, despite guidelines in the United States
and Europe that recommend it for many patients
during pregnancy (7,8).SEE PAGE 2692There has never been a randomized trial comparing
different anticoagulation regimens in pregnant
women with MHVs, and current guidelines are largely
devised on the basis of case series and expert
consensus. The most widely cited systematic review
(6) was written before the use of low-molecular-
weight heparin (LMWH) and included many patients
with older-generation ball-in-cage valves, thereby
limiting the relevance of this review in contemporary
patients. Subsequent systematic reviews and meta-
analyses have included women on ﬁxed-dose
LMWH, which is now known to be associated with
catastrophic valve failure (9,10).
The goal of this meta-analysis was to estimate the
risk of adverse maternal and fetal outcomes among
different anticoagulation regimens in a contemporary
population of pregnant women with modern MHVs.
METHODS
STUDY SELECTION. Studies were identiﬁed through
a Medline review using the following search terms:
“(mechanical valve OR heart disease OR valve
replacement OR heart valve) AND pregnancy AND
(unfractionated heparin OR heparin OR low molecular
weight heparin OR enoxaparin OR warfarin OR low
dose warfarin OR oral anticoagulation OR Coumadin
OR coumarin OR anticoagulation).” Publications up to
June 5, 2016, were included in the search. Each
publication was independently adjudicated by 2 of
the authors (Z.L.S. and E.V.K.) to determine eligibility
for inclusion in the meta-analysis.
Study inclusion required unambiguous reporting of
outcomes of interest in pregnant women with MHVs
who had anticoagulant therapy with a VKA, LMWH, or
unfractionated heparin (UFH). Studies were excluded
in the following circumstances: if >10% of reported
pregnancies occurred in women with ball-in-cagevalves; if ﬁxed doses of either UFH or LMWH were
administered; if <5 pregnancies were reported; if
pregnancies either were not followed to term or the
reported anticoagulation regimen was initiated after
the ﬁrst trimester; if results had previously been
published; or if studies were published in a language
other than English. Studies reporting outcomes in
individuals with mechanical tricuspid or pulmonic
valves, in which right-sided valve dysfunction was
not speciﬁcally reported on, were also excluded out of
concern that these valves are at a higher risk for
thrombosis and dysfunction (11–15) that could skew
the study results. Attempts were made to include all
studies reporting on left-sided MHVs. Results from
studies reporting outcomes from both right- and left-
sided MHVs, in which valve dysfunction was clearly
identiﬁed as right sided or left sided, were included.
If, however, the position of the dysfunctional valve
could not be discerned, the study was excluded. In-
vestigators of each study that met inclusion criteria
were contacted if additional data were required.
Four anticoagulation regimens were included in
this meta-analysis: 1) VKAs continued throughout the
entirety of pregnancy (VKA); 2) dose-adjusted LMWH
for the entirety of pregnancy (LMWH); 3) dose-
adjusted LMWH for the ﬁrst trimester, followed by a
VKA for the remainder (LMWH and VKA); and 4) dose-
adjusted UFH for the ﬁrst trimester, followed by a VKA
for the remainder (UFH and VKA). We also identiﬁed
women who received low-dose warfarin, deﬁned as
#5 mg of daily warfarin in individuals able to maintain
a therapeutic international normalized ratio (INR).
OUTCOMES AND DEFINITIONS. The primary
maternal outcome was deﬁned as a composite of
maternal death, prosthetic valve failure, and systemic
thromboembolism. Prosthetic valve failure was
deﬁned as abnormal valve function leading to a
clinically meaningful outcome, such as heart failure,
arrhythmia, or reoperation. Thromboembolism was
deﬁned as any systemic arterial thrombotic event,
such as stroke or transient ischemic attack. The pri-
mary fetal outcome was deﬁned as a composite of
spontaneous abortion, fetal death, and the presence
of any congenital defect. The deﬁnition of sponta-
neous abortion was not uniform among the included
studies. Spontaneous abortion was deﬁned as any
unplanned fetal loss before 20 weeks of gestation in
16 studies (16–31), 22 weeks in 1 study (32), and 24
weeks in 1 study (33). Fetal death was deﬁned as any
unplanned fetal loss at or after 20 weeks of gestation
in 16 studies (16–31), 22 weeks in 1 study (32), and 24
weeks in 1 study (33). To avoid misclassiﬁcation, we
used the deﬁnition provided by each individual
FIGURE 1 Study Search Flowchart
Excluded (n = 578)
Unrelated topic
Excluded (n = 137)
Met exclusion criteria
1) < 5 cases (63)
2) > 10% Ball-in-cage valves (23)
3) Outcomes of interest not reported (18)
4) Language other than English (15)
5) Subtherapeutic INR target, fixed dose
LMWH, or fixed dose UFH (8)
6) Duplicate reporting of data (6)
7) Included TVR and/or PVR (2)
8) Pregnancies not followed to term or started
following pregnancy after the first trimester (2)
Literature search
(n = 825)
Articles remaining
(n = 247)
Articles remaining
(n = 155)
Included studies
(n = 18)
Excluded (n = 92)
No primary data
1) Review article (86)
2) Meta-analyses/systematic review (6)
The number and types of studies captured by the search terms. INR ¼ international
normalized ratio; LMWH ¼ low-molecular-weight heparin; PVR ¼ pulmonary valve
replacement; TVR ¼ tricuspid valve replacement; UFH ¼ unfractionated heparin.
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deﬁned as warfarin embryopathy or any unexpected
congenital anomaly for gestational age (excluding
patent ductus arteriosus in premature infants).
Secondary outcomes included the incidence of
maternal death, composite of prosthetic valve failure
and systemic thromboembolism, spontaneous abor-
tion, fetal death, and congenital defects.
STATISTICAL ANALYSIS. For the estimation of an
average risk of the composite maternal and fetal
outcomes, a mixed-effects meta-regression model
was ﬁtted on the transformed risks from individual
studies, with the different regimens as ﬁxed effects
(using VKA, regardless of dose, as the reference) and
the different cohorts of women receiving a speciﬁc
regimen within studies as random effects. For the
analysis, a double-arcsine variance-stabilizing trans-
formation (34,35) was applied to the calculated risks,
which allowed the inclusion of cohorts reporting zero
events without adding a continuity correction (36).
The means of the transformed risks estimated from
the meta-regression were then back-transformed (37)
to provide an average estimate of maternal and fetal
risk for each cohort.
To compare the meta-analytic averaged risks
among strategies, an estimate of their ratio was per-
formed and is referred to as the ratio of averaged risks
(RAR). The 95% conﬁdence intervals (CIs) for the
RARs were obtained using parametric bootstrap,
which involved sampling from a multivariate normal
distribution assumed for the estimated coefﬁcients
from the meta-regression and their covariance matrix
and then applying the corresponding back-
transformation. Sensitivity analyses were conducted
by sampling from a multivariate noncentral Student
t test distribution. Here we emphasize that the RAR
should not be mistaken for an estimate of relative risk
because it provides only a measure of the difference
among regimens on the risks of adverse events,
averaged over different groups of women from
nonrandomized observational studies.
In a secondary analysis focusing on adverse fetal
outcomes, each alternative regimen (LMWH, LMWH
and VKA, and UFH and VKA) was compared with a
reference regimen of women receiving low-dose
warfarin (#5 mg daily warfarin) throughout
pregnancy. Sensitivity analyses were performed to
account for potential misreporting of outcomes. From
these analyses, we report the number of unreported
events that would have had to occur to change the
results of the main analysis signiﬁcantly.
All analyses were carried out using the statistical
software R (R Project for Statistical Computing,Vienna, Austria) (38), and the meta-regression model
was ﬁtted using the metafor package (39). We used
restricted maximum likelihood for the estimation of
the between-cohort variance.
RESULTS
Of the 825 publications identiﬁed through the Med-
line search, 579 were on an unrelated topic, 92 did
not include primary patient-related data (e.g., review
papers, editorials), and 137 met the exclusion criteria
(Figure 1). Eighteen studies, totaling 800 pregnancies
between 1974 and 2014, were included in the ﬁnal
analysis (16–33) (Table 1). Patients in 8 of the studies
were followed prospectively. Ten studies reported on
maternal and fetal outcomes with a VKA regimen in
which most patients were taking warfarin, with a
small number of patients taking either acenocou-
marol or phenprocoumon. Eight studies reported on
maternal and fetal outcomes with an LMWH regimen
using enoxaparin and dalteparin. Dose adjustment of
LMWH was administered on the basis of anti–factor
Xa levels in all 8 studies. Four studies reported on
TABLE 1 Characteristics of Included Studies
First Author, Year (Ref. #)
Country of
Origin Regimens
Pregnancies
(% of Total) Dose Adjustment Valve Types
Pregnancy
Date Range
Ayad et al., 2016 (32) Egypt VKA
UFH þ VKA
17 (4)
28 (15)
INR
NR þ INR
Bileaﬂet: NR
Tilting disk: NR
Ball-in-cage: NR
NR
van Hagen et al., 2015 (33) Multinational VKA
LMWH
LMWH þ VKA
UFH þ VKA
38 (8)
17 (20)
31 (72)
47 (25)
INR
Anti–factor Xa level
Anti–factor Xa level þ INR
NR þ INR
Bileaﬂet: NR
Tilting disk: NR
Ball-in-cage: NR
2008–2014
Hassouna and Allam, 2014 (16) Egypt Low-dose warfarin 55 (34) INR Bileaﬂet: 100% 1991–2013
Samiei et al., 2012 (19) Iran VKA
UFH þ VKA
43 (9)
10 (5)
INR
PTT þ INR
Bileaﬂet: 79%
Tilting disk: NR
Ball-in-cage: NR
1999–2009
Basude et al., 2012 (17) United Kingdom VKA
LMWH
LMWH þ VKA
22 (5)
4 (5)
6 (13)
INR
Anti–factor Xa level
Anti–factor Xa level þ INR
Bileaﬂet: 94%
Tilting disk: 6%
2003–2011
De Santo et al., 2012 (18) Italy Low-dose warfarin
LMWH
16 (10)
1 (1)
INR
Anti–factor Xa level
Bileaﬂet: 100% 2000–2010
Khamoushi et al., 2011 (20) Iran VKA
Low-dose warfarin
UFH þ VKA
38 (8)
29 (18)
11 (6)
INR
INR
PTT þ INR
Bileaﬂet: NR
Tilting disk: NR
Ball-in-cage: 0%
2002–2007
Saeed et al., 2011 (21) South Africa LMWH 8 (10) Anti–factor Xa level Bileaﬂet: 100% 2007–2009
Quinn et al., 2009 (23) United Kingdom LMWH
LMWH þ VKA
11 (13)
1 (2)
Anti–factor Xa level
Anti–factor Xa level þ INR
Bileaﬂet: NR
Tilting disk: NR
Ball-in-cage: NR
2001–2007
Yinon et al., 2009 (24) Canada LMWH 23 (28) Anti–factor Xa level Bileaﬂet: 81%
Tilting disk: 14%
Ball-in-cage: 5%
1998–2008
Abildgaard et al., 2009 (22) Norway LMWH 12 (14) Anti–factor Xa level Bileaﬂet: 92%
Tilting disk: 8%
1997–2008
Khamooshi et al., 2007 (25) Iran VKA
Low dose warfarin
UFH þ VKA
142 (29)
62 (38)
54 (29)
INR
INR
PTT þ INR
Bileaﬂet: 50%
Tilting disk: 50%
1974–2000
Kim et al., 2007 (26) Korea VKA
UFH þ VKA
5 (1)
18 (10)
INR
PTT þ INR
Bileaﬂet: 100% 1990–2005
Descarries et al., 2006 (27) Canada LMWH þ VKA 5 (12) Anti–factor Xa level þ INR Bileaﬂet: 100% 1999–2005
Nassar et al., 2004 (28) Lebanon VKA 30 (6) INR Bileaﬂet: 51%
Tilting disk: NR
Ball-in-cage: NR
1987–2002
Bauersachs and Lindhoff-Last,
2003 (29)
Germany LMWH 7 (8) Anti–factor Xa level Bileaﬂet: NR
Tilting disk: NR
Ball-in-cage: NR
1997–2000
Srivastava et al., 2002 (31) India VKA 37 (8) INR Bileaﬂet: 34%
Tilting disk: 63%
Ball-in-cage: 3%
1989–1998
Al-Lawati et al., 2002 (30) Oman VKA
UFH þ VKA
42 (9)
21 (11)
INR
PTT þ INR
Bileaﬂet: 33%
Tilting disk: 67%
NR
INR ¼ international normalized ratio; LMWH ¼ low–molecular-weight heparin; NR ¼ not reported; PTT ¼ partial thromboplastin time; UFH ¼ unfractionated heparin;
VKA ¼ vitamin K antagonist.
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LMWH and VKA, and all 4 studies administered
LMWH doses on the basis of anti–factor Xa levels.
Seven studies reported on maternal and fetal
outcomes with a regimen of UFH and VKA; 5 of these
studies reported dose-adjusted UFH on the basis of
partial thromboplastin time levels, and 2 studies did
not report the method for monitoring of UFH. Four
studies reported fetal outcomes with a low-dose
warfarin regimen. With the exception of 1 study
(33), every patient was transitioned to UFH before
delivery.Data on the percentage of pregnant women with
ball-in-cage valves were missing in 6 studies. Of
these, only 1 study included pregnancies before 1998
and accounted for 6% of the total VKA cohort (28).
The majority of published outcomes for the VKA, UFH
and VKA, and low-dose warfarin regimens originated
from Asia, Africa, and the Middle East (85%, 90%, and
76% of pregnancies, respectively). Most published
outcomes for the LMWH regimen originated from
Europe and North America (79%). Most published
outcomes for the LMWH and VKA regimen originated
from a multinational study (72%); however, the
FIGURE 2 Forest Plot of the Composite Maternal Outcome
Strategy/Study
VKA
Pregnancies
42
37
30
142
5
38
22
16
43
55
38
17
7
12
11
23
8
4
1
17
Al-Lawati, 2002
Srivastava, 2002
Nassar, 2004
Khamooshi, 2007
Kim, 2007
Khamoushi, 2011
Basude, 2012
De Santo, 2012
Samiei, 2012
Hassouna, 2014
van Hagen, 2015
Ayad, 2016
LMWH
Bauersachs, 2003
Abildgaard, 2009
Quinn, 2009
Yinon, 2009
Saeed, 2011
Basude, 2012
De Santo, 2012
van Hagen, 2015
0 [0,0]
0 [0,0]
0 [0,0]
11 [5,6]
0 [0,0]
3 [1,2]
0 [0,0]
0 [0,0]
4 [1,3]
0 [0,0]
2 [1,1]
0 [0,0]
0 [0,0]
2 [0,2]
1 [0,1]
1 [1,0]
0 [0,0]
3 [1,2]
1 [0,1]
2 [1,1]
5
1
6
31
LMWH + VKA
Descarries, 2006
Quinn, 2009
Basude, 2012
van Hagen, 2015
1 [0,1]
0 [0,0]
1 [0,1]
3 [0,3]
21
54
18
11
10
47
28
UFH + VKA
Al-Lawati, 2002
Khamooshi, 2007
Kim, 2007
Khamoushi, 2011
Samiei, 2012
van Hagen, 2015
Ayad, 2016
2 [0,2]
11 [2,9]
0 [0,0]
6 [0,6]
5 [0,5]
1 [0,1]
4 [0,4]
0 (0, 8)
0 (0, 9)
0 (0, 12)
8 (4, 13)
0 (0, 52)
8 (2, 21)
0 (0, 15)
0 (0, 21)
9 (3, 22)
0 (0, 6)
5 (1, 18)
0 (0, 20)
0 (0, 41)
17 (2, 48)
9 (0, 41)
4 (0, 22)
0 (0, 37)
75 (19, 99)
100 (3, 100)
12 (1, 36)
20 (1, 72)
0 (0, 98)
17 (0, 64)
10 (2, 26)
10 (1, 30)
20 (11, 34)
0 (0, 19)
55 (23, 83)
50 (19, 81)
2 (0, 11)
14 (4, 33)
Risk, % Risk, % (95% CI)Events*
Strategy Pregnancies
485
83
43
189
0 20 40 60 80 100
VKA
LMWH
LMWH + VKA
UFH + VKA
20 [8,12]
10 [3,7]
5 [0,5]
29 [2,27]
5 (2, 9)
15 (8, 25)
16 (5, 32)
16 (9, 24)
Averaged risk, %
Averaged risk, %
(95% CI)Events* 
Total Total
The individual and composite maternal endpoints as reported by each publication included in the meta-analysis. The forest plot represents an
averaged risk of the composite outcome, weighted by study sample size. *Values in brackets are number of deaths, number of prosthetic
valve failures or thromboembolisms. CI ¼ conﬁdence interval; VKA ¼ vitamin K antagonist; other abbreviations as in Figure 1.
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FIGURE 3 Forest Plot of the Composite Fetal Outcome
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of fetal deaths, number of births with congenital defects. Abbreviations as in Figures 1 and 2.
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FIGURE 4 Maternal Composite Outcome
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Ratio of Averaged Risks
Maternal composite outcome
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Ratio [95% CI]
Ratio of the meta-analytic averaged risk for the maternal composite outcome between a
VKA regimen and each alternative regimen. Abbreviations as in Figures 1 and 2.
FIGURE 5 Fetal Composite Outcome
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B
(A) Ratios of the meta-analytic averaged risk for the fetal composite outcome between
a VKA regimen and each alternative regimen. (B) Ratio of averaged risk for the fetal
composite outcome between a low-dose VKA regimen and the alternative regimens.
Abbreviations as in Figures 1 and 2.
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2687investigators reported that most patients with this
regimen were treated in developed countries (33).
The study-speciﬁc risks of the composite maternal
and fetal outcomes are reported in forest plots
(Figures 2 and 3), along with the estimated averaged
risks for each regimen, obtained from the mixed-
effects meta-regression model on the double-arcsine
transformed risks. The estimated averaged risk
of the maternal composite outcome was 5.0%
(95% CI: 2.5% to 8.5%) for the VKA regimen, 15.5%
(95% CI: 7.6% to 25.4%) for the LMWH regimen, 15.9%
(95% CI: 4.9% to 31.6%) for the regimen of LMWH and
VKA, and 15.8% (95% CI: 9.2% to 23.8%) for the
regimen of UFH and VKA. Compared with women who
received a VKA regimen, the average risk of an adverse
maternal eventwas signiﬁcantly higher amongwomen
who received an LMWH regimen (RAR: 3.1; 95% CI: 1.3
to 7.5) or a regimen of UFH and VKA (RAR: 3.1; 95% CI:
1.5 to 7.4), with a trend toward signiﬁcance in women
who received a regimen of LMWH and VKA (RAR: 3.2;
95% CI: 0.9 to 8.8) (Figure 4). The number of reported
maternal deaths was low across all regimens, and
consequently, the incidence of systemic thromboem-
bolism and/or valve failure was largely responsible for
the observed differences among groups.
The estimated averaged risk of the fetal composite
outcome was 39.2% (95% CI: 27.0 to 52.1) for the VKA
regimen, 13.9% (95% CI: 3.7 to 29.0) for the LMWH
regimen, 16.4% (95% CI: 1.5 to 41.2) for the regimen of
LMWH and VKA, and 33.6% (95% CI: 18.4 to 50.8) for
the regimen of UFH and VKA. Compared with the VKA
regimen, the averaged risk of an adverse fetal
event was signiﬁcantly lower in patients with the
LMWH regimen (RAR: 0.4; 95% CI: 0.1 to 0.8)
(Figure 5A). No signiﬁcant difference was observed
for the remaining anticoagulation regimens. In a
subgroup of individuals taking low-dose warfarin, the
estimated averaged risk of the fetal composite
outcomewas 4.8% (95% CI: 0.0 to 16.9). When the low-
dose warfarin regimen was compared with the alter-
native regimens, no signiﬁcant differences in fetal risk
were observed in comparison with the LMWH regimen
(RR: 0.9; 95% CI: 0.3 to 2.1) (Figure 5B).
The number of babies born with congenital defects
was unavailable in 1 study reporting outcomes of 3
pregnancies using an LMWH regimen (4.8% of the
LMWH cohort) (17), and it was assumed to be zero in
the main analysis. The conclusion of the analysis re-
mains unchanged if all 3 babies in this group are
assumed to have had congenital defects. Overall,
congenital defects and fetal deaths were uncommon
events in all groups, with the incidence of sponta-
neous abortion largely responsible for the observed
differences among regimens.Two studies were excluded because it could not be
determined whether outcomes occurred in women
with right-sided or left-sided MHVs (40,41). This
decision resulted in the exclusion of 9 pregnancies in
women with left-sided MHVs who had a regimen of
UFH and VKA and the exclusion of 41 pregnancies
in women with left-sided MHVs who had a VKA
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conclusions of the maternal outcomes analysis
remained unchanged when assuming that all re-
ported maternal events in the VKA group occurred in
individuals with left-sided MHVs and that none of the
reported maternal events in the group taking UFH
and VKA occurred in individuals with left-sided
MHVs (Online Table 1). Similarly, the conclusions of
the fetal outcomes analysis remain unchanged
regardless of how many of the 6 reported fetal events
occurred in individuals with left-sided MHVs who
had an anticoagulation regimen of UFH and VKA
(Online Table 2).
A signiﬁcant amount of heterogeneity was present
in the estimates of risk among studies. Heterogeneity
was estimated to account for 44% (95% CI: 18% to
82%) of the variability of the averaged risk estimates
of the maternal composite outcome and for 81% (95%
CI: 67% to 90%) of the total variability of the averaged
risk estimates of the fetal composite outcome, as
displayed by the statistic I2 (Online Tables 3 and 4).
DISCUSSION
On the basis of this contemporary meta-analysis of
800 pregnancies in women with MHVs and modern
anticoagulation regimens, VKA is the anticoagulation
regimen associated with the lowest risk of adverse
maternal outcomes. This ﬁnding is consistent with
those of previous publications (6,9,10), despite the
differences in the patients studied; we included many
fewer women with ball-in-cage valves and included a
study group of women taking dose-adjusted LMWH.
The risk of adverse maternal outcomes with dose-
adjusted LMWH throughout pregnancy is higher
than that of a VKA regimen. This is balanced by a
signiﬁcant reduction in adverse fetal outcomes.
However, on comparison with a subset of individuals
who continued taking #5 mg of warfarin throughout
the duration of pregnancy, no signiﬁcant difference
in fetal risk was observed, thus supporting the notion
that warfarin’s teratogenic effects are dose depen-
dent (42). Although the risk of maternal thrombo-
embolic complications remains a concern with
LMWH, we report a lower incidence of this compli-
cation, compared with previously published meta-
analyses (9,10). The exclusion of ﬁxed-dose LMWH
regimens likely accounts for this difference and
further strengthens the argument for the use of dose-
adjusted LMWH with anti–factor Xa levels during
pregnancy. The use of a regimen of LMWH and VKA
was not observed to have a lower risk of adverse
maternal outcomes, compared with an LMWH
regimen, despite the use of a VKA for the majority ofeach pregnancy. Our data lack granularity with regard
to the trimester in which the majority of adverse
maternal events occurred, but a possible explanation
is that the risk of thrombosis is highest in the ﬁrst
trimester of pregnancy, when VKA risk to the fetus is
highest. This could also explain the high incidence of
adverse maternal outcomes observed with a regimen
of UFH and VKA. It is notable that although the use of
a VKA was associated with a high incidence of spon-
taneous abortion, the incidence of fetal death was
quite low, a ﬁnding supporting the idea that fetal risk
to VKA exposure is highest during early gestation (4).
It is also important to recognize that the relative
reduction in adverse fetal outcomes with these
regimens, compared with VKA, is likely to be signiﬁ-
cantly underestimated if the comparison warfarin
group is limited to individuals who must continue
taking >5 mg of warfarin daily to maintain a
therapeutic INR, although this comparison was not
performed in the current study.
Our results support the American College of
Cardiology and American Heart Association guide-
lines for the management of patients with valvular
heart disease, which recommend the use of low-dose
warfarin in women who are able to maintain thera-
peutic INRs (Class IIa) over the use of either ﬁrst
trimester LMWH or UFH use (Class IIb) (7). It is notable
that despite ﬁndings supportive of these guidelines,
only 4 of the referenced publications in the valve
guidelines were included in our analysis because of
our stringent inclusion and exclusion criteria.
STUDY LIMITATIONS. The data obtained for this
meta-analysis were observational, not randomized.
Therefore, direct comparisons among regimens using
the RARs should be regarded as exploratory and must
be interpreted with caution, given the possibility of
confounders. For example, the observed differences
in adverse maternal and fetal outcomes among anti-
coagulation regimens may have been inﬂuenced by
the underlying cardiac disorder (e.g., rheumatic vs.
congenital heart disease) that led to valve replace-
ment. Additionally, the data for speciﬁc anti-
coagulation regimens were clustered by region, thus
introducing the possibility that differences in access
to health care could have inﬂuenced outcomes. Sec-
ond, there is a paucity of published data reporting
maternal and fetal outcomes in pregnant women with
modern MHVs who are receiving many of the newer
anticoagulation regimens, and this scarcity increases
the likelihood of a type II error. This may explain the
similarity in adverse fetal events between the VKA
regimen and the 2 regimens that withhold VKA for the
ﬁrst trimester. Third, our data lack the granularity to
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This illustration depicts maternal and fetal risk with different anticoagulation regimens. Maternal risk is lowest on a vitamin K antagonist (VKA) regimen, and fetal risk is
lowest on a low-molecular-weight heparin (LMWH) regimen. The risk of either a maternal or fetal complication during pregnancy is lowest with a low-dose warfarin
regimen; however, even low-dose warfarin carries a substantial risk of a poor outcome. CI ¼ conﬁdence interval.
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2689determine the trimester in which each maternal event
occurred, thereby making it difﬁcult to assess
whether individuals receiving heparin in the ﬁrst
trimester and a VKA in the second and third
trimesters had a thrombotic event while taking
heparin or a VKA. Finally, our composite outcomes do
not include maternal hemorrhage, premature
delivery, fetal intracranial hemorrhage, and neonatal
death because of underreporting and nonuniform
deﬁnitions of these adverse events. These outcomes,
as well as others, are important considerations when
determining optimal anticoagulation regimens in this
patient population, and they highlight the impor-
tance of prospective registries with standardized
reporting, such as the ROPAC (Registry of Pregnancy
and Cardiac Disease) study of pregnancy in women
with MHVs (33).The signiﬁcant heterogeneity observed in the
estimated risks is likely multifactorial. As mentioned
earlier, our analysis included studies from a large
geographic distribution and included patients from
regions with vastly different access to health care,
which may have resulted in greater heterogeneity.
Additionally, heterogeneity was greatest for the
composite fetal outcome, which was largely driven by
the incidence of spontaneous abortions. One expla-
nation for this ﬁnding is the apparent dose-
dependent effects of VKAs on the developing fetus.
It is possible that differences in the distribution of
VKA doses among studies were responsible for
much of the observed heterogeneity. However, given
that most studies included in this group did not
report the distribution of VKA doses, we were unable
to verify or explicitly model this hypothesis in the
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In pregnant women with
prosthetic MHVs, the use of LMWH as an alternative
to VKA anticoagulants results in less fetal loss but a
higher incidence of maternal complications. The risk
of VKA exposure to the fetus is dose dependent, with
relatively low rates of adverse maternal and fetal
outcomes with warfarin at doses #5 mg daily.
TRANSLATIONAL OUTLOOK: The basis of current
knowledge of maternal and fetal risks of anticoagu-
lation is a small number of observational studies, and
larger, prospective studies are needed to validate
these ﬁndings.
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2690meta-regression. The random effects analysis allowed
us to account and quantify the heterogeneity among
the estimates from the different studies; however, as
a result, studies were weighted more uniformly in the
analysis. Consequently, smaller, less-precise studies
may have had a greater impact on the study results.
As such, we performed an analysis using a ﬁxed-
effects model to estimate maternal and fetal risk.
Similar results were obtained, with the exception that
fetal risk in women receiving LMWH and VKA was
8%, one-half of what was estimated using the random
effects model. This ﬁnding has little impact on our
study conclusions and further supports the notion
that avoidance of VKAs in the ﬁrst trimester of preg-
nancy improves fetal risk.
Despite these limitations, we believe that reporting
these data is important to clinical practice because no
randomized data currently exist and randomized
trials are unlikely, given the complex ethical and
social issues involved in choosing an anticoagulation
regimen for pregnant women. Therefore, our inten-
tion is to consolidate all contemporary primary data
relating to this subject, so that practitioners and
patients alike gain a greater understanding of the
strength of the data that are the basis for current
recommendations.
Our meta-analysis consolidates the current experi-
ence with up-to-date anticoagulant regimens in
contemporary study patients with modern MHVs.
Additionally, our study focuses on all 4 anti-
coagulation regimens for pregnant women with MHVs
endorsed by the 2014 American College of Cardiology
and American Heart Association valve guidelines (7).
Our ﬁndings support the current recommendations
put forth by the guidelines (Central Illustration).
However, our analysis excludes individuals with right-
sided MHVs, thus making the results of this study less
clinically applicable in this patient population.
CONCLUSIONS
VKAs represent the safest anticoagulation regimen
for pregnant women with mechanical aortic and/or
mitral valves. The adverse effects of VKAs on fetaldevelopment appear to be limited to early gestation,
with low incidences of fetal demise and congenital
defects at warfarin doses of #5 mg daily. The use of
anti–factor Xa–adjusted LMWH, either throughout
pregnancy or during the ﬁrst trimester, followed by
warfarin use for the remainder of pregnancy, is
associated with higher adverse maternal outcomes as
compared with a VKA regimen, but with lower
adverse fetal outcomes. However, no difference in
adverse fetal outcomes was observed between
individuals taking warfarin at doses #5 mg daily and
those with an LMWH regimen. The use of a regimen
of UFH and VKA continues to demonstrate a high risk
of adverse maternal outcomes, without a substan-
tially lower risk of adverse fetal outcomes as
compared with a VKA regimen. Prospective random-
ized studies and large patient registry databases are
needed to validate these observations.
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